Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
In this issue, we present another installment of our quarterly
review of pharmaceutical/biotechnology dealmaking – for the
third quarter of 2010. Our data come from Elsevier's Strategic
Transactions.
Amanda Micklus, Maureen Riordan and Theresa Surprenant